Squadron Capital Management LLC Acquires 9.8% Stake in InMed Pharmaceuticals Inc.

On May 27, 2026, Squadron Capital Management, LLC filed a Schedule 13G indicating a new substantial holding in InMed Pharmaceuticals Inc. (INM). As of the event date of May 19, 2026, the reporting group, which includes Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, collectively reported beneficial ownership of 325,000 common shares. This position represents approximately 9.8% of the company's outstanding common stock, based on 3,314,063 shares outstanding as reported in the issuer's most recent quarterly filing. The filing specifies that Squadron Capital Management, LLC serves as the investment adviser to private funds, including Squadron Master Fund LP, and may be deemed to have shared voting and dispositive power over the shares. Matthew Sesterhenn and William Blank, as Partners of the investment adviser, also share beneficial ownership. The acquisition was reported under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer. This represents a significant increase from a previous position of zero shares.